| 何玉金,殷 娟,朱安东,张长江,刘 磊.继发性甲状旁腺机能亢进患者在血透基础上联用骨化三醇后ALP、iPTH指标变化探究[J].,2021,(4):781-784 |
| 继发性甲状旁腺机能亢进患者在血透基础上联用骨化三醇后ALP、iPTH指标变化探究 |
| ALP and IPTH Index Levels in Patients with Secondary Hyperthyroidism Combined with Calcitriol Based on Hemodialysis |
| 投稿时间：2020-07-07 修订日期：2020-07-31 |
| DOI：10.13241/j.cnki.pmb.2021.04.039 |
| 中文关键词: 继发性甲旁亢 血液透析 骨化三醇 甲状旁腺亢进 |
| 英文关键词: Secondary hyperthyroidism Hemodialysis Calcitriol Hyperparathyroidism |
| 基金项目:国家自然科学基金项目（81270265） |
|
| 摘要点击次数: 753 |
| 全文下载次数: 499 |
| 中文摘要: |
| 摘要 目的：探讨继发性甲状旁腺机能亢进患者在血透基础上联用骨化三醇后全段甲状旁腺激素（intact parathyroid hormone，iPTH）、碱性磷酸酶（alkaline phosphatase，ALP）指标变化情况。方法：选取我院2019年1月到2019年12月共收治的维持血液性透析继发性甲旁亢患者80例，随机分为两组，每组40例，给予对照组常规治疗方式，给予观察组在血透基础上联用骨化三醇治疗，对比两组的治疗效果、血液相关指标变化以及不良反应的发生情况。结果：对照组治疗总有效率为72.5 %，观察组的治疗总有效率为90.0 %，观察组明显优于对照组（P＜0.05）；两组治疗前iPTH、ALP、磷（P）、钙（Ca）无明显差异（P＞0.05），治疗后观察组前iPTH、ALP、P、Ca相关血液指标明显优于对照组（P＜0.05）；对比两组不良反应发现，患者在治疗后不良反应发生率无明显差异（P＞0.05）。结论：对继发性甲旁亢患者在血透基础上联用骨化三醇能够提高患者的治疗效果，改善患者相关血液指标情况，而且不良反应发生情况与常规治疗没有明显差异，安全可靠，值得临床应用推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the changes of ALP and iPTH indexes in patients with secondary hyperthyroidism combined with calcitriol on the basis of hemodialysis. Methods: A total of 80 patients with secondary hyperthyroidism who maintained hemodialysis who were admitted to our hospital from January 2019 to December 2019 were selected as the research object. The patients were randomly divided into an observation group and a control group. Each group of 40 patients was given The patients in the control group were given conventional treatment, and the patients in the observation group were treated with calcitriol on the basis of hemodialysis, and the treatment effects, changes in blood-related indicators, and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the control group was 72.5 %, and the total effective rate in the observation group was 90.0 %. The observation group was significantly better than the control group (P<0.05). The iPTH, ALP, P, Ca of the two groups of patients before treatment There was no significant difference (P>0.05). After treatment, the blood parameters related to iPTH, ALP, P, and Ca in the observation group were significantly better than those in the control group (P<0.05). Comparing the adverse reactions between the two groups, the incidence of adverse reactions after treatment was found in the patients There was no significant difference (P>0.05). Conclusion: Combined use of calcitriol on the basis of hemodialysis in patients with secondary hyperthyroidism can improve the patient's treatment effect and improve the patient's related blood indicators, and the occurrence of adverse reactions is not significantly different from conventional treatment. It is safe and reliable, and is worthy of clinical Application promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
